ICD-10 Coding for Metastatic Renal Cell Carcinoma(C34.90P, C41.9P, C64.1)
Comprehensive guide on ICD-10 coding for metastatic renal cell carcinoma, including primary and metastatic site codes, documentation requirements, and coding pitfalls.
Complete code families applicable to Metastatic Renal Cell Carcinoma
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C64.1 | Malignant neoplasm of right kidney, except renal pelvis | Use when RCC is confirmed in the right kidney. |
|
| C64.2 | Malignant neoplasm of left kidney, except renal pelvis | Use when RCC is confirmed in the left kidney. |
|
| C78.00 | Secondary malignant neoplasm of unspecified lung | Use for confirmed lung metastasis from RCC. |
|
| C79.51 | Secondary malignant neoplasm of bone | Use for confirmed bone metastasis from RCC. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutMetastatic Renal Cell Carcinoma
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Metastatic Renal Cell Carcinoma.
Omitting laterality in RCC documentation
Impact
Clinical: Inaccurate treatment planning., Regulatory: Non-compliance with coding standards., Financial: Potential claim denials.
Mitigation
Always document laterality in clinical notes., Verify imaging reports for laterality.
Using C79.31 without confirming primary RCC
Impact
Reimbursement: Incorrect coding may lead to denied claims., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data representation.
Mitigation
Always link secondary sites to primary RCC code.
Using Z85.5 during active therapy
Impact
Reimbursement: Claims may be denied for using history code., Compliance: Non-compliance with active treatment coding., Data Quality: Misrepresentation of patient's current condition.
Mitigation
Use C64.x for active disease, not history codes.
Metastatic site documentation
Impact
Failure to document all metastatic sites can lead to audit issues.
Mitigation
Implement checklist for documenting all metastatic sites.